People
Let’s take a look at some of the professionals moving to transition the pharma and biotech world this past week.
After Unity Biotechnology chief executive officer Keith Leonard was on CNBC’s “Power Lunch,” touting the company’s therapeutic approach to longevity and aging, company shares soared almost 18 percent.
Days after a report by The New York Times and ProPublica revealed José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, failed to disclose his vast financial ties to various companies in journal articles, the noted cancer researcher has resigned from his position.
Prof. Dr. Helga Rübsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH are one of three teams nominated for the German President’s Award for Innovation in Science and Technology 2018
Arix Bioscience plc today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors.
Paris-based Sanofi announced it is refocusing two of its international business units. The goal is to create more focus on mature markets and emerging markets.
GeoVax Labs, Inc. announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will deliver a talk during the 12th Vaccine Congress, organized by Elsevier and Vaccine journal, being held September 16-19, 2018 in Budapest, Hungary.
Takeda Pharmaceuticals will shutter its Deerfield, Ill. U.S. headquarters and move the operations to Boston as the company consolidates its operations following the $62 billion acquisition of Shire.
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
Nirmal Mulye, chief executive officer of Missouri-based Nostrum Laboratories, is looking to take over Martin Shkreli’s mantle of being the poster-boy for drastic drug price increases.
PRESS RELEASES